High
22.025
Open
21.340
VWAP
21.65
Vol
1.13M
Mkt Cap
1.84B
Low
20.950
Amount
24.43M
EV/EBITDA(TTM)
20.70
Total Shares
95.22M
EV
1.59B
EV/OCF(TTM)
7.81
P/S(TTM)
1.66
Progyny, Inc. is a benefit management company. The Company specializes in fertility and family building benefits solutions in the United States. The Company’s clients include various employers across an array of industries. It has contracts to provide coverage to approximately 6.4 million employees and their partners (known as members). The Company provides its benefits through its proprietary Smart Cycle approach. Smart Cycles include the medical services required for a member’s full course of treatment, including all necessary diagnostic testing and access to the technology. In addition to its fertility benefits solution, the Company offers an integrated pharmacy benefits solution, Progyny Rx, which can be added by its clients. Progyny Rx provides its members with access to the medications needed during their fertility treatment. It provides care management services, as well as medication administration training, pharmacy support services and continuing patient care advocate support.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
294.78M
-1.22%
0.358
-14.68%
291.50M
+1.7%
0.367
-8.33%
315.69M
+3.82%
0.415
-3.49%
Estimates Revision
The market is revising Upward the revenue expectations for Progyny, Inc. (PGNY) for FY2025, with the revenue forecasts being adjusted by 1.12% over the past three months. During the same period, the stock price has changed by -2.27%.
Revenue Estimates for FY2025
Revise Upward
+1.12%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-0.97%
In Past 3 Month
Stock Price
Go Down
-2.27%
In Past 3 Month
10 Analyst Rating
26.37% Upside
Wall Street analysts forecast PGNY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PGNY is 27.17 USD with a low forecast of 21.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
6 Hold
0 Sell
Moderate Buy
26.37% Upside
Current: 21.500
Low
21.00
Averages
27.17
High
30.00
26.37% Upside
Current: 21.500
Low
21.00
Averages
27.17
High
30.00
BTIG
David Larsen
Hold
to
Strong Buy
Upgrades
$28
2025-03-31
Reason
BTIG
David Larsen
Price Target
$28
2025-03-31
Upgrades
Hold
to
Strong Buy
Reason
BTIG analyst David Larsen upgraded Progyny to Buy from Neutral with a $28 price target.
Canaccord Genuity
Richard Close
Hold
Maintains
$17 → $23
2025-02-28
Reason
Canaccord Genuity
Richard Close
Price Target
$17 → $23
2025-02-28
Maintains
Hold
Reason
B of A Securities
Michael Cherny
Strong Buy
Maintains
$21 → $25
2025-02-11
Reason
B of A Securities
Michael Cherny
Price Target
$21 → $25
2025-02-11
Maintains
Strong Buy
Reason
JP Morgan
Anne Samuel
Hold
Maintains
$17 → $23
2025-01-28
Reason
JP Morgan
Anne Samuel
Price Target
$17 → $23
2025-01-28
Maintains
Hold
Reason
JP Morgan
Anne Samuel
Buy
to
Hold
Downgrades
$22 → $17
2024-12-02
Reason
JP Morgan
Anne Samuel
Price Target
$22 → $17
2024-12-02
Downgrades
Buy
to
Hold
Reason
JPMorgan downgraded Progyny to Neutral from Overweight with a price target of $17, down from $22. The company's recent struggles with utilization and attrition "have presented a set of challenges for the story that are difficult to overcome," the analyst tells investors in a research note. The firm says a path to resolution in the near term is less clear, resulting in a lack of catalysts to get the story going, with long-term targets more difficult to achieve given the near-term setbacks.
Barclays
Sarah James
Buy
Maintains
$30 → $17
2024-11-14
Reason
Barclays
Sarah James
Price Target
$30 → $17
2024-11-14
Maintains
Buy
Reason
Barclays analyst Stephanie Davis lowered the firm's price target on Progyny to $17 from $30 and keeps an Overweight rating on the shares. The stock dropped 11% post the earnings call as better than feared selling season results were overshadowed by the third consecutive cut on atypical usage, sowing model fears, the analyst tells investors in a research note. The firm looks to proof points of forecasting, but notes a more prudent approach to the company's guidance.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Progyny Inc (PGNY.O) is 13.54, compared to its 5-year average forward P/E of 125.85. For a more detailed relative valuation and DCF analysis to assess Progyny Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
125.85
Current PE
13.54
Overvalued PE
309.56
Undervalued PE
-57.86
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Undervalued
5Y Average EV/EBITDA
28.11
Current EV/EBITDA
8.32
Overvalued EV/EBITDA
47.08
Undervalued EV/EBITDA
9.14
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Undervalued
5Y Average PS
4.15
Current PS
1.52
Overvalued PS
6.40
Undervalued PS
1.90
Financials
Annual
Quarterly
FY2025Q1
YoY :
+16.53%
324.04M
Total Revenue
FY2025Q1
YoY :
+30.49%
24.17M
Operating Profit
FY2025Q1
YoY :
-10.88%
15.06M
Net Income after Tax
FY2025Q1
YoY :
0.00%
0.17
EPS - Diluted
FY2025Q1
YoY :
+88.75%
46.97M
Free Cash Flow
FY2025Q1
YoY :
+4.23%
23.39
Gross Profit Margin - %
FY2025Q1
YoY :
-6.00%
16.14
FCF Margin - %
FY2025Q1
YoY :
-23.52%
4.65
Net Margin - %
FY2025Q1
YoY :
-17.80%
10.11
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
270.9K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
2
5.2M
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
166.7K
Volume
1
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
4
27.5K
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
8.0K
USD
1
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
270.9K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
2
5.2M
USD
Months
0-12
0
0.0
USD
Months
PGNY News & Events
Events Timeline
(ET)
2025-05-29
09:06:29
Progyny adds Elizabeth Bierbower to board of directors
2025-05-14 (ET)
2025-05-14
09:11:16
Progyny appoints Gloria Richard-Davis, Whitney Booker to Medical Advisory Board
2025-05-08 (ET)
2025-05-08
16:40:37
Progyny sees FY25 adjusted EPS $1.54-$1.64, consensus $1.60
Sign Up For More Events
Sign Up For More Events
News
Preview
5.0
05-29NewsfilterProgyny Adds Distinguished Healthcare Executive Elizabeth Bierbower to Board of Directors
Preview
5.0
05-21NASDAQ.COM10.6% of VHT Holdings Seeing Recent Insider Buys
Preview
5.0
05-14NewsfilterProgyny Appoints Two Renowned Women's Health Experts to Medical Advisory Board
Sign Up For More News
People Also Watch
CHCO
City Holding Co
117.890
USD
-1.16%
OXLC
Oxford Lane Capital Corp
4.530
USD
+1.34%
SIMO
Silicon Motion Technology Corp
61.200
USD
-2.90%
MBIN
Merchants Bancorp
32.020
USD
-2.26%
ROG
Rogers Corp
66.570
USD
-1.13%
TARS
Tarsus Pharmaceuticals Inc
42.950
USD
-1.13%
GOGL
Golden Ocean Group Ltd
7.700
USD
+3.22%
AKRO
Akero Therapeutics Inc
49.650
USD
+3.37%
GDYN
Grid Dynamics Holdings Inc
12.530
USD
-1.34%
ELPC
Companhia Paranaense de Energia
8.190
USD
-0.56%
FAQ
What is Progyny Inc (PGNY) stock price today?
The current price of PGNY is 21.5 USD — it has increased 0.75 % in the last trading day.
What is Progyny Inc (PGNY)'s business?
What is the price predicton of PGNY Stock?
What is Progyny Inc (PGNY)'s revenue for the last quarter?
What is Progyny Inc (PGNY)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Progyny Inc (PGNY)'s fundamentals?
How many employees does Progyny Inc (PGNY). have?